- United Kingdom
- /
- Life Sciences
- /
- AIM:PYC
Physiomics First Half 2025 Earnings: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2024)
Physiomics (LON:PYC) First Half 2025 Results
Key Financial Results
- Revenue: UK£354.0k (down 7.3% from 1H 2024).
- Net loss: UK£231.0k (loss widened by 12% from 1H 2024).
- UK£0.001 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Physiomics shares are down 11% from a week ago.
Risk Analysis
Before you take the next step you should know about the 5 warning signs for Physiomics that we have uncovered.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:PYC
Physiomics
Provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland.
Flawless balance sheet moderate.
Market Insights
Community Narratives
